Traditional Chinese medicine polysaccharide with lipid-lowering activity as well as preparation method and application thereof

Abstract

The invention discloses a traditional Chinese medicine polysaccharide with lipid-lowering activity and a preparation method and application thereof, and relates to the technical field of biological medicine, the traditional Chinese medicine polysaccharide is allium macrostemon neutral homogeneous polysaccharide ACP1, the weight-average molecular weight is 17.96 kDa, the polydispersity index is 1.726, and the traditional Chinese medicine polysaccharide is composed of glucose and fructose according to the molar ratio of 2.53%: 97.47%. The allium macrostemon neutral homogeneous polysaccharide provided by the invention is a new neutral homogeneous polysaccharide ACP1 extracted from allium macrostemon, can effectively improve oleic acid-induced AML-12 cell lipid deposition, and has remarkable lipid-lowering activity and high safety. The preparation method of the allium macrostemon neutral homogeneous polysaccharide is good in repeatability, the obtained neutral homogeneous polysaccharide is high in purity, and industrial production is facilitated.

Description

Technical Field

[0001] This invention relates to the field of biomedicine, and more specifically to a traditional Chinese medicine polysaccharide with lipid-lowering activity, its preparation method, and its application. Background Technology

[0002] In recent years, the incidence of cardiovascular diseases has continued to rise, and hyperlipidemia is one of its core pathological mechanisms. Currently, statins are commonly used clinically for control; however, although statins can inhibit HMG-CoA reductase (the rate-limiting enzyme in cholesterol synthesis), long-term use can easily lead to liver damage and myopathy. Therefore, there is an urgent need to find safe and effective new drugs.

[0003] The traditional Chinese medicine *Allii macrostemonis* Bulbus is the dried bulb of *Allium macrostemon* Bunge or *Allium chinense* G. Don, both belonging to the Liliaceae family. It possesses the effects of promoting yang and dispersing stagnation, regulating qi and relieving stagnation. Modern research has confirmed its potential for lowering lipids and preventing atherosclerosis, and it is commonly used in the treatment of cardiovascular diseases. As a medicinal and edible herb recorded in the *Shennong Bencao Jing* (Shennong's Classic of Materia Medica), *Allii macrostemonis* Bulbus's bulb is rich in polysaccharides. Current research on the therapeutic effects of *Allii macrostemonis* Bulbus on cardiovascular diseases focuses primarily on the polysaccharides from *Allium macrostemon* Bunge's bulb, while the activity of these polysaccharides remains unclear. A few studies have investigated the extraction and purification processes of *Allium macrostemon* polysaccharides (e.g., Chinese invention patent application number 202411273222.0), but no reports have been found on the homogeneous polysaccharides of *Allium chinense* Bulbus.

[0004] Therefore, extracting high-purity polysaccharides with lipid-lowering activity from Allium macrostemon to develop and treat cardiovascular diseases is a technical problem that urgently needs to be solved by those skilled in the art. Summary of the Invention

[0005] In view of this, the present invention provides a traditional Chinese medicine polysaccharide with lipid-lowering activity, its preparation method and application.

[0006] To achieve the above objectives, the present invention adopts the following technical solution:

[0007] A traditional Chinese medicine polysaccharide with lipid-lowering activity, wherein the traditional Chinese medicine polysaccharide is Allium macrostemon neutral homogeneous polysaccharide ACP1, with a weight average molecular weight of 17.96 kDa and a polydispersity index of 1.726, and is composed of glucose and fructose in a molar ratio of 2.53%:97.47%.

[0008] As a preferred technical solution, the neutral homogeneous polysaccharide backbone of the *Allium macrostemon* is composed of →6)-β-D-Fruf-(2→ and →1,6)-β-D-Fruf-(2→ and an internal →6)-α-D-Glcp-(1→, and the side chains are composed of →1)-β-D-Fruf-(2→ and β-D-Fruf-(2→).

[0009] As a more preferred technical solution, the main structure of the neutral homogeneous polysaccharide of *Allium macrostemon* is as follows: .

[0010] Another object of the present invention is to provide a method for preparing the above-mentioned lipid-lowering polysaccharide from traditional Chinese medicine, comprising the following steps:

[0011] S1: Preparation of Allium macrostemon ACP: Fresh Allium macrostemon bulbs were cut into small pieces and defatted with ethanol to obtain residue; the residue was extracted with water to obtain extract; the extract was concentrated and then precipitated with ethanol, and the precipitate was Allium macrostemon ACP.

[0012] S2: Preparation of neutral homogeneous polysaccharide ACP1 from Allium macrostemon: The crude polysaccharide ACP from Allium macrostemon was reconstituted with water, and the protein was removed by papain combined with the Sevage method and the supernatant was collected; ethanol was added again for precipitation, and the precipitate was washed with an organic solvent; after reconstitution with water, the precipitate was dialyzed, and the obtained dialysate was purified by anion exchange column chromatography. Water was used for elution and the eluent was collected. The obtained eluent was dried to obtain neutral homogeneous polysaccharide ACP1 from Allium macrostemon.

[0013] As a preferred technical solution, the preparation of crude polysaccharide ACP from Allium macrostemon (S1) is as follows: fresh Allium macrostemon bulbs are chopped and then extracted with 7 times the amount of 95% ethanol solution by reflux extraction for 2 hours; the residue is then extracted twice with 7 times the amount of water at 85 ℃ for 2 hours each time; the two extracts are combined and concentrated, and then precipitated by standing at 4 ℃ with 80% ethanol for 24 hours, and the precipitate is collected.

[0014] As a preferred technical solution, the preparation of neutral homogeneous polysaccharide ACP1 from *Allium macrostemon* using method S2 is as follows: The crude polysaccharide obtained in S1 is reconstituted in water, followed by the addition of papain and incubation at 60 °C for 5 hours. Proteins are removed using the Sevage method, with a chloroform to n-butanol ratio of 5:1. After standing for 2 hours, the mixture is centrifuged, and the supernatant is collected. This process is repeated 5 times. Anhydrous ethanol is added to the supernatant to adjust the ethanol concentration to 80% for precipitation. The precipitate is then washed sequentially with anhydrous ethanol and acetone. The precipitate is reconstituted with water and dialyzed using a dialysis bag with a molecular weight cutoff of 3.5 kDa. The obtained dialysate is purified by chromatography using a DEAE cellulose DE-52 anion exchange column, eluted with water at a flow rate of 1 mL / min for a volume of 350 mL. The eluent is collected, and all the obtained water eluent is concentrated and dried to obtain the neutral homogeneous polysaccharide from *Allium macrostemon*.

[0015] Another object of the present invention is to provide the application of the above-mentioned lipid-lowering polysaccharide or the lipid-lowering polysaccharide prepared by the above-mentioned method in the preparation of lipid-lowering drugs.

[0016] Beneficial effects:

[0017] The neutral homogeneous polysaccharide ACP1 provided by this invention is a novel neutral homogeneous polysaccharide extracted from Allium tuberosum. It has been identified as mainly composed of fructose and its fine structure does not contain acidic or basic groups. It can effectively improve oleic acid-induced lipid deposition in AML-12 cells and has significant lipid-lowering activity.

[0018] The method for preparing homogeneous polysaccharides from Allium macrostemon provided by this invention has good reproducibility and yields high purity neutral homogeneous polysaccharides, which is beneficial for industrial production. Attached Figure Description

[0019] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the drawings used in the description of the embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are only embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on the provided drawings without creative effort.

[0020] Figure 1 The HPGPC-MALLS-RID chromatogram of the neutral homogeneous polysaccharide (ACP1) from Example 2 is shown below.

[0021] Figure 2 The UV spectrum of neutral allium homopolysaccharide (ACP1) in Example 2;

[0022] Figure 3 The infrared spectrum of neutral allium homopolysaccharide (ACP1) in Example 2;

[0023] Figure 4 The neutral allium homopolysaccharide (ACP1) in Example 2 1 H NMR spectrum;

[0024] Figure 5 The neutral allium homopolysaccharide (ACP1) in Example 2 13 C NMR spectrum;

[0025] Figure 6 This is a schematic diagram of the main structure of the allium neutral homogeneous polysaccharide (ACP1) in Example 2;

[0026] Figure 7 This study describes the therapeutic effect of homogeneous polysaccharide (ACP1) from *Allium macrostemon* (CN) on an oleic acid-induced lipid deposition model in AML-12 cells, as described in Example 3. CN was the control group, MOD was the model group, FB was the positive control group (fenofibrate), and the remaining groups contained different doses of homogeneous polysaccharide (ACP1). ### p<0.001 vs CN; *** p<0.001 vs MOD). Detailed Implementation

[0027] The technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0028] Example 1: Preparation of neutral homogeneous polysaccharide from Allium macrostemon

[0029] (1) Preparation of crude polysaccharide from Allium macrostemon (ACP)

[0030] 10 kg of fresh Allium tuberosum bulbs were chopped and extracted with 70 L of 95% ethanol solution using the reflux extraction method for 2 hours. The residue was then extracted twice with 7 times the amount of water at 85 °C for 2 hours each time. The two extracts were combined and concentrated to 4 L. Then, 16 L of anhydrous ethanol was added and the mixture was allowed to stand at 4 °C for 24 hours. The precipitate was collected, and the obtained precipitate was Allium tuberosum crude polysaccharide (ACP). The crude drug yield was 23.55%.

[0031] (2) Preparation of neutral homogeneous polysaccharide (ACP1) from Allium macrostemon

[0032] The crude polysaccharide (ACP) obtained in the previous step was reconstituted in 2 L of water, followed by the addition of 100 g of papain and incubation at 60 ℃ for 5 hours. Proteins were removed using the Sevage method. 400 mL of chloroform and 80 mL of n-butanol were added, mixed thoroughly, and allowed to stand for 2 hours before centrifugation. The supernatant was collected, and this process was repeated 5 times. Anhydrous ethanol was added to adjust the ethanol concentration to 80% for precipitation. The precipitate was washed successively with anhydrous ethanol and acetone. The precipitate was reconstituted with water and dialyzed using a dialysis bag with a molecular weight cutoff of 3.5 kDa. The obtained dialysate was purified by chromatography using a DEAE cellulose DE-52 anion exchange column, eluted with water at a flow rate of 1 mL / min for a volume of 350 mL. The eluent was collected, and all the water eluent was concentrated and dried to obtain neutral homogeneous polysaccharide (ACP1), with a crude drug yield of 3.2%.

[0033] Example 2 Structural characterization of neutral homogeneous polysaccharides from Allium macrostemon

[0034] 1. The molecular weight and purity of the neutral homogeneous polysaccharide (ACP1) obtained in Example 1 were analyzed by HPGPC-MALLS-RID chromatography.

[0035] The chromatographic column used was a Shodex OH-pak SB-805 HQ (300×8 mm) and a Shodex OH-pak SB-803 HQ (300×8 mm) in series. The mobile phase was a 0.1 M NaNO3 aqueous solution containing 0.02% NaN3. The column temperature was 45 ℃, the flow rate was 0.6 mL / min, and the injection volume was 100 μL. The dn / dc value of the analyte in the 0.1 M NaNO3 aqueous solution containing 0.02% NaN3 was 0.141 mL / g.

[0036] The results are attached. Figure 1 As shown, the polysaccharide obtained in Example 1 exhibits a single symmetrical peak, indicating that it is a homogeneous polysaccharide. HPGPC analysis determined the homogeneous monosaccharide purity to be 99.2%. In this example, a differential detector was used to detect the sample concentration based on its refractive index, and a multi-angle laser light scattering instrument was used to detect the light scattering information of the macromolecules. The corresponding molecular weight was calculated using the Mark-Houwink Equation. The chromatographic data were processed using ASTRA 6.1 software. An absolute molecular weight analysis graph was plotted with the retention time (Time, min) as the x-axis and the molar mass (g / mol) as the y-axis. The weight-average molecular weight (Mw) of the homogeneous polysaccharide (ACP1) obtained in Example 1 was calculated to be 17.96 kDa, and the polydispersity index (Mw / Mn) was 1.726.

[0037] 2. The UV-Vis spectrum of the allium neutral homogeneous polysaccharide (ACP1) obtained in Example 1 was analyzed using a UV spectrophotometer.

[0038] The UV-Vis spectra of neutral homogeneous polysaccharide (ACP1) from *Allium macrostemon* were detected in the range of 200–800 nm using a UV spectrophotometer. The results are shown in the attached figure. Figure 2 As shown, the neutral homogeneous polysaccharide (ACP1) obtained in Example 1 has no obvious absorption peaks at 260 nm and 280 nm, meaning that it contains neither protein nor nucleic acid.

[0039] 3. The IR spectrum of the allium neutral homogeneous polysaccharide (ACP1) obtained in Example 1 was analyzed using an infrared spectrometer.

[0040] Infrared spectroscopy was used in the range of 4000 ~ 400 cm⁻¹. -1 The IR spectrum of neutral homogeneous polysaccharide (ACP1) from Allium macrostemon was detected within the specified range, and the results are attached. Figure 3 As shown, functional group analysis was performed on the neutral homogeneous polysaccharide (ACP1) obtained in Example 1, and its concentration at 3410 cm⁻¹ was [data missing]. -1 and 1640 cm -1 The absorption peaks were attributed to the stretching and bending vibrations of OH, respectively; 2937 cm⁻¹ -1 and 1500~1200 cm -1 The absorption peaks are attributed to CH stretching and bending vibrations, respectively; 1128 cm⁻¹ -1 and 1029 cm -1 The absorption peak indicates the presence of furanose residues in the neutral homogeneous polysaccharide (ACP1) of Allium macrostemon; 930 cm⁻¹ -1 and 818 cm -1 The absorption peak is attributed to fructose with β-glycosidic bonds.

[0041] 4. Monosaccharide composition analysis was performed on the homogeneous polysaccharide (ACP1) from *Allium macrostemon* (Example 1). 2.41 mg of ACP1 was added to 1 mL of 2M trifluoroacetic acid solution and heated at 60 °C for 1 hour. Nitrogen gas was then introduced, and the mixture was dried. Methanol was added for washing, and the mixture was dried again. This methanol washing process was repeated 2-3 times. The mixture was then dissolved in a suitable amount of sterile water and transferred to a chromatographic vial for analysis. The chromatographic column used was a Dionex™ CarboPac™ PA-20 (150*3.0 mm, 10 μm). Mobile phase A was H2O, mobile phase B was 0.1 M NaOH, and mobile phase C was 0.1 M NaOH and 0.2 M NaAc. The flow rate was set to 0.5 mL / min, the injection volume to 5 μL, and the column temperature to 30 °C. Electrochemical detection revealed that the monosaccharide components of ACP1 included glucose and fructose, as shown in Table 1.

[0042] Table 1. Monosaccharide components of neutral homogeneous polysaccharide (ACP1) from Allium macrostemon.

[0043] 5. Methylation analysis of the neutral homogeneous polysaccharide (ACP1) from Example 1.

[0044] Samples were sequentially subjected to methylation, hydrolysis, reduction, and acetylation. The results of GC-MS analysis were then compared with a standard mass spectrum library. The GC-MS conditions were as follows: a BPX70 column (30 m × 0.25 mm × 0.25 µm, SGE, Australia); injection volume of 1 μL; split ratio of 10:1; high-purity helium as carrier gas; flow rate of 1.5 mL / min; initial column temperature of 140 ℃, held for 2 min, then programmed to 230 ℃ at 3 ℃ / min, held for 3 min; ion source temperature of 200 ℃; MS quadrupole temperature of 110 ℃; ionization energy of 50 eV; transfer line temperature of 210 ℃; mass scan range (m / z): 50–350.

[0045] Methylation analysis revealed that the neutral homogeneous polysaccharide (ACP1) of Allium macrostemon possesses a variety of glycosidic bonds as shown in Table 2.

[0046] Table 2. Analysis results of methylated sugar alcohol acetate of neutral homogeneous polysaccharide (ACP1) from Allium macrostemon.

[0047] The methylation analysis above shows that the neutral homogeneous polysaccharide (ACP1) has a repeatable unit structure. Its main chain consists of →6)-β-D-Fruf-(2→ and →1,6)-β-D-Fruf-(2→ and an internal →6)-α-D-Glcp-(1→, and the side chain consists of →1)-β-D-Fruf-(2→ and β-D-Fruf-(2→).

[0048] 6. Nuclear magnetic resonance (NMR) analysis of the neutral homogeneous polysaccharide (ACP1) from Example 1.

[0049] Weigh 30 mg of neutral homogeneous polysaccharide from Allium macrostemon, dissolve it in 0.5 mL of heavy water, and collect the sample using a 600 MHz nuclear magnetic resonance spectrometer. 1 HNMR spectrum and 13 C10 NMR spectrum.

[0050] The results are attached. Figure 4 As shown, 1 The 1H NMR spectrum showed that the terminal hydrogen of glucose was δ=5.36 ppm, while fructose, being a ketose, had no terminal hydrogen signal; see attached. Figure 5 As shown,13 The C10 NMR spectrum shows that the terminal carbon signal of fructose is δ=102~105 ppm, and the terminal carbon signal of glucose is δ=92.02 ppm. The structure of the homogeneous polysaccharide (ACP1) can also be verified using these NMR spectral data. The main structural diagram of the homogeneous polysaccharide (ACP1) is attached. Figure 6 As shown.

[0051] In summary, the neutral homogeneous polysaccharide (ACP1) prepared in Example 1 is a neutral homogeneous polysaccharide with a weight-average molecular weight (Mw) of 17.96 kDa and a polydispersity index (Mw / Mn) of 1.726. Infrared spectroscopy shows that it exhibits typical polysaccharide absorption peaks, including one at 3410 cm⁻¹. -1 The hydroxyl absorption peak is at 930 cm⁻¹. -1 and 818 cm -1 The β-glycosidic bond fructose absorption peak is located at 1700 cm⁻¹. -1 No carbonyl absorption peak was observed, consistent with the absence of an absorption peak at 280 nm in the UV spectrum. GC-MS analysis revealed that the main chain of the homogeneous polysaccharide (ACP1) consists of →6)-β-D-Fruf-(2→ and →1,6)-β-D-Fruf-(2→ and an internal →6)-α-D-Glcp-(1→, while the side chains consist of →1)-β-D-Fruf-(2→ and β-D-Fruf-(2→), consistent with the monosaccharide composition analysis results.

[0052] Example 3: Activity Verification of Neutral Homogeneous Polysaccharides from Allium macrostemon

[0053] This embodiment uses an oleic acid-induced lipid deposition model in AML-12 cells to investigate the effect of neutral homogeneous polysaccharide from Allium macrostemon on blood lipids: AML-12 cells in logarithmic growth phase (Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences) were used at a concentration of 1×10⁻⁶ cells / cells. 4 The wells were seeded at a density of 1 / 2 wells in 96-well plates. The control group (CN) was added to DMEM / F12 medium containing 1% FBS. The model group (MOD), positive control group (FB), and drug groups with different concentrations of Allium macrostemon 1 (ACP1) were all added to 1% FBS-DMEM / F12 medium containing 1 mM oleic acid. The plates were incubated at 37 ℃ for 24 hours. The supernatant of each well was then discarded. The control group and model group were added to DMEM / F12 medium containing 2% FBS, the positive control group was added to 2% FBS-DMEM / F12 medium containing 100 μM fenofibrate, and the drug groups were added to 2% FBS-DMEM / F12 medium containing 0.125 mg / mL, 0.25 mg / mL, 0.5 mg / mL, 1.0 mg / mL, and 2.0 mg / mL of Allium macrostemon 1 (ACP1), respectively. The plates were incubated at 37 ℃ for 24 hours.

[0054] After incubation, discard the supernatant from each well, rinse once with 100 μL of PBS, and discard. Add 100 μL of 4% fixative to each well, fix at 4 °C for 30 min, and discard. Rinse once with 100 μL of PBS, and discard. Then add 20 μL of 0.3% Oil Red solution to each well, stain in the dark for 15 min, and discard. Rinse twice with 100 μL of PBS, and discard. Finally, add 100 μL of DMSO to each well, mix for 10 min using a plate mixer, and measure the OD value at 358 nm for each group using a microplate reader to indirectly quantify the deposition level of neutral lipids (mainly triglycerides and cholesterol esters) in cells.

[0055] The results are attached. Figure 7 As shown, the neutral homogeneous polysaccharide (ACP1) of Allium macrostemon can effectively improve oleic acid-induced lipid deposition in AML-12 cells at concentrations of 0.125~2.0 mg / mL, exhibiting significant lipid-lowering activity. Moreover, as a natural biomacromolecule, it has better safety.

[0056] The various embodiments in this specification are described in a progressive manner, with each embodiment focusing on the differences from other embodiments. The same or similar parts between the various embodiments can be referred to each other.

[0057] The above description of the disclosed embodiments enables those skilled in the art to make or use the invention. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the invention. Therefore, the invention is not to be limited to the embodiments shown herein, but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.

Claims

1. A traditional Chinese medicine polysaccharide with lipid-lowering activity, characterized in that, The polysaccharide in question is a neutral homogeneous polysaccharide ACP1 from Allium macrostemon, with a weight-average molecular weight of 17.96 kDa and a polydispersity index of 1.

726. It is composed of glucose and fructose in a molar ratio of 2.53% to 97.47%.

2. The traditional Chinese medicine polysaccharide with lipid-lowering activity according to claim 1, characterized in that, The neutral homogeneous polysaccharide backbone consists of →6)-β-D-Fruf-(2→ and →1,6)-β-D-Fruf-(2→ and an inner →6)-α-D-Glcp-(1→, and the side chains consist of →1)-β-D-Fruf-(2→ and β-D-Fruf-(2→).

3. The traditional Chinese medicine polysaccharide with lipid-lowering activity according to claim 2, characterized in that, The main structure of the neutral homogeneous polysaccharide of *Allium macrostemon* is as follows: 。 4. The method for preparing the lipid-lowering polysaccharide of traditional Chinese medicine according to any one of claims 1-3, characterized in that, Includes the following steps: S1: Preparation of Allium macrostemon ACP: Fresh Allium macrostemon bulbs were cut into small pieces and defatted with ethanol to obtain residue; the residue was extracted with water to obtain extract; the extract was concentrated and then precipitated with ethanol, and the precipitate was Allium macrostemon ACP. S2: Preparation of neutral homogeneous polysaccharide ACP1 from Allium macrostemon: The crude polysaccharide ACP from Allium macrostemon was reconstituted with water, and the protein was removed by papain combined with the Sevage method and the supernatant was collected; ethanol was added again for precipitation, and the precipitate was washed with an organic solvent; after reconstitution with water, it was dialyzed, and the obtained dialysate was purified by anion exchange column chromatography. Water was used for elution and the water eluent was collected. The obtained eluent was concentrated and dried to obtain neutral homogeneous polysaccharide ACP1 from Allium macrostemon.

5. The method for preparing the lipid-lowering polysaccharide of traditional Chinese medicine according to claim 4, characterized in that, The preparation of crude polysaccharide ACP from Allium macrostemon S1 is as follows: Fresh Allium macrostemon bulbs are chopped and then extracted with 7 times the amount of 95% ethanol solution by reflux extraction for 2 hours; the residue is then extracted twice with 7 times the amount of water at 85 ℃ for 2 hours each time; the two extracts are combined and concentrated, and then precipitated by standing at 4 ℃ with 80% ethanol for 24 hours, and the precipitate is collected.

6. The method for preparing the lipid-lowering polysaccharide from traditional Chinese medicine according to claim 4, characterized in that, The preparation of neutral homogeneous polysaccharide ACP1 from S2 is as follows: The crude polysaccharide obtained in S1 is redissolved in water, then papain is added, and the mixture is incubated at 60 ℃ for 5 hours. The protein is removed using the Sevage method with a chloroform to n-butanol ratio of 5:

1. After standing for 2 hours, the mixture is centrifuged, and the supernatant is collected. This process is repeated 5 times. Anhydrous ethanol is added to the supernatant to adjust the ethanol concentration to 80% for precipitation. The precipitate is then washed successively with anhydrous ethanol and acetone. The precipitate is redissolved in water and dialyzed using a dialysis bag with a molecular weight cutoff of 3.5 kDa. The obtained dialysate is purified by chromatography using a DEAE cellulose DE-52 anion exchange column with water as the eluting agent at a flow rate of 1 mL / min and an elution volume of 350 mL. The eluent is collected, and all the obtained water eluent is concentrated and dried to obtain neutral homogeneous polysaccharide from S.

7. The use of the traditional Chinese medicine polysaccharide with lipid-lowering activity as described in any one of claims 1-3 or the traditional Chinese medicine polysaccharide with lipid-lowering activity prepared by any one of claims 4-6 in the preparation of lipid-lowering drugs.

Images